Derek J. Jonker

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Sharlene Gill · 5 shared papers, 2012–2026 · strength 0.62
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
2. Chris J. O’Callaghan · 4 shared papers, 2016–2026 · strength 0.59
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
3. Daniel John Renouf · 4 shared papers, 2012–2026 · strength 0.56
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
4. Ravi Ramjeesingh · 3 shared papers, 2022–2026 · strength 0.54
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
5. Mustapha Ali Tehfe · 3 shared papers, 2022–2026 · strength 0.54
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
6. Petr Kavan · 3 shared papers, 2022–2026 · strength 0.54
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
7. Christina Kim · 3 shared papers, 2022–2026 · strength 0.54
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
8. James Thomas Topham · 3 shared papers, 2022–2026 · strength 0.54
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
9. Félix Couture · 3 shared papers, 2022–2026 · strength 0.54
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
10. Jennifer Jane Knox · 3 shared papers, 2022–2026 · strength 0.54
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
    • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
11. David F. Schaeffer · 3 shared papers, 2022–2026 · strength 0.54
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
    • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
12. Joanna M. Karasinska · 2 shared papers, 2026 · strength 0.42
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
13. Yoo‐Joung Ko · 2 shared papers, 2022–2026 · strength 0.33
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
14. Steve Gallinger · 1 shared paper, 2026 · strength 0.21
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
15. Faiyaz Notta · 1 shared paper, 2026 · strength 0.21
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
16. George Zogopoulos · 1 shared paper, 2026 · strength 0.21
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
17. Malcolm J. Moore · 3 shared papers, 2012–2016 · strength 0.11
    • Paper Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase… DOI 10.1016/j.pan.2016.08.013↗
    • Paper Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase… DOI 10.1016/j.ejca.2011.10.035↗
    • Paper A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic ca… DOI 10.1007/s10637-010-9611-3↗
18. Michael M. Vickers · 2 shared papers, 2012–2016 · strength 0.08
    • Paper Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase… DOI 10.1016/j.pan.2016.08.013↗
    • Paper Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase… DOI 10.1016/j.ejca.2011.10.035↗
19. Wendy R. Parulekar · 2 shared papers, 2012–2016 · strength 0.08
    • Paper Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase… DOI 10.1016/j.pan.2016.08.013↗
    • Paper Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase… DOI 10.1016/j.ejca.2011.10.035↗
20. Gillian K. Gresham · 1 shared paper, 2014 · strength 0.06
    • Paper Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. DOI 10.1186/1471-2407-14-471↗
21. David Goldstein · 1 shared paper, 2016 · strength 0.05
    • Paper Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase… DOI 10.1016/j.pan.2016.08.013↗
22. Chee Khoon Lee · 1 shared paper, 2016 · strength 0.05
    • Paper Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase… DOI 10.1016/j.pan.2016.08.013↗
23. David William Hedley · 1 shared paper, 2012 · strength 0.03
    • Paper A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic ca… DOI 10.1007/s10637-010-9611-3↗
24. Lesley Seymour · 1 shared paper, 2012 · strength 0.03
    • Paper A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic ca… DOI 10.1007/s10637-010-9611-3↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.